Many drugs are just fine years after they 'expire,' study finds
October 9, 2012 by Karen Kaplan in Medications
Chances are, your medicine cabinet contains some pills that are past their expiration date. You might even have some pain relievers, some cough syrup or some sleeping pills that were purchased back when Richard Nixon was in the White House. But you can't seem to throw them away because you suspect they might still be OK to take.
If you've wondered whether medicines really do need to be tossed after their expiration date, you've got some company at the California Poison Control System, the University of California, San Francisco, and UC Irvine. Researchers from those institutions decided to satisfy their curiosity by testing the effectiveness of eight drugs that had been sitting around, unopened, in pharmacies for years after they had supposedly gone bad.
These drugs were not just a few years past their prime, these medications were a full 28 to 40 years past their official expiration dates.
The eight drugs contained a total of 15 active ingredients. The researchers couldn't find a standard test for one of them (homatropine), so they focused their analysis on the other 14.
The tablets and capsules were dissolved and subjected to chemical analysis using a mass spectrometer. That revealed how much of the active ingredients remained in the pills.
Out of the 14 active ingredients, 12 were still at high enough concentration - 90 percent of the amount stated on the label - to qualify as having "acceptable potency," the researchers found. These included:
-Acetaminophen (the pain reliever in Tylenol)
-Codeine (an opiate that treats pain and coughs)
-Hydrocodone (an opiate used to treat moderate to severe pain)
-Phenacetin (an analgesic that's not used much anymore)
-Caffeine (a stimulant)
-Chlorpheniramine (an antihistamine used to treat colds and allergies)
-Pentobarbital (a short-acting barbiturate)
-Butalbital (a barbiturate that lasts for an intermediate period of time)
-Secobarbital (a barbituate used to treat insomnia)
-Phenobarbital (a barbiturate that controls seizures and relieves anxiety)
-Meprobamate (a tranquilizer to treat anxiety)
-Methaqualone (a sedative and muscle relaxant known by the brand name Quaaludes)
The only active ingredients that missed that cutoff were aspirin and the stimulant amphetamine.
The expiration date on a drug is usually one to five years after it was manufactured. But those dates are often set arbitrarily, since the Food and Drug Administration doesn't require pharmaceutical makers to test how long the active ingredients will last, the researchers wrote.
They noted that the Shelf-Life Extension Program allows drugs in federal stockpiles to be retained for up to 278 months after their stated expiration date if tests show they are still potent. But some of the ingredients tested in this study remained good for 480 months - so far.
The research team's obvious conclusion? "Our results support the effectiveness of broadly extending expiration dates for many drugs," they wrote.
"The most important implication of our study involves the potential cost savings resulting from lengthier product expiration dating," they added. "Given that Americans currently spend more than $300 billion annually on prescription medications, extending drug expiration dates could yield enormous health care expenditure savings."
The analysis was published online Monday by Archives of Internal Medicine.
Journal reference:
JAMA Internal Medicine
(c)2012 Los Angeles Times
Distributed by MCT Information Services
-
FDA: Novartis recall may also affect painkillers
Jan 09, 2012 |
not rated yet |
0
-
FDA warns of fake version of ADHD drug Adderall
May 30, 2012 |
not rated yet |
0
-
Fentanyl transdermal patch recall expanded
Mar 03, 2008 |
not rated yet |
0
-
Simple new test to combat counterfeit drug problem in developing countries
Aug 19, 2012 |
not rated yet |
0
-
Public confused about ingredients in pain relievers
May 03, 2011 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013
-
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013
-
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
- More from Physics Forums - Medical Sciences
More news stories
Merck ends development of Parkinson's disease drug
(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.
Medications
May 23, 2013 |
1 / 5 (1) |
0
J&J expects 10-plus new drug applications by 2017
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
Medications
May 23, 2013 |
5 / 5 (1) |
0
Experts favor US approval of Merck sleeping pill (Update)
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications
May 22, 2013 |
not rated yet |
0
Glaxo, US partnering to develop new antibiotics
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
Medications
May 22, 2013 |
not rated yet |
0
Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine
The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...
Medications
May 22, 2013 |
not rated yet |
0
Engineered cytomegalovirus protects monkeys from HIV equivalent
(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...
Researchers identify first drug targets in childhood genetic tumor disorder
Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...
Hormone levels may provide key to understanding psychological disorders in women
Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.
Going live: Immune cell activation in multiple sclerosis
Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...
Help at hand for people with schizophrenia
How can healthy people who hear voices help schizophrenics? Finding the answer for this is at the centre of research conducted at the University of Bergen.
Alzheimer's disease, the soft target of the euthanasia debate
(Medical Xpress)—The way Alzheimer's disease is portrayed by advocacy groups and the media is having undue influence on the euthanasia debate, according to a Deakin University nursing ethics professor.